A Phase 1/2 Study Of Cmc-544 Administered In Combination With Rituximab In Subjects With Follicular Or Diffuse Large B-cell Non-hodgkin's Lymphoma
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Inotuzumab ozogamicin (Primary) ; Rituximab
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions
- Sponsors Pfizer
- 23 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 10 Jan 2014 In ClinicalTrials.gov, status is changed recruiting from active, no longer recruiting. But as the end date is nearing, I have not updated it.
- 04 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.